Mirvetuximab (Mirvetuximab) single-bottle price analysis

Somituximab (Mirvetuximab) is a type of antibody-conjugated drug developed specifically for tumors with high FRα expression. It has attracted much attention in international cancer treatment in recent years. The core feature of this drug is to accurately identify the folate receptor α on the surface of cancer cells and release the cytotoxic load into the tumor cells, thereby achieving a more targeted killing effect while reducing damage to normal tissue. This mechanism makes somituximab an important treatment option for certain ovarian cancers and related gynecological tumors, especially for patients who have received multiple lines of therapy but still have disease progression. It has entered clinical practice in the United States and Europe, and has gradually formed a clearer medication path.

The drug is currently on the market in China, but has not yet been included in medical insurance, so its cost has become a key concern for patients. According to existing market information, the domestic price of a 100mg tube is about 110,000 yuan, which is a relatively high-priced innovative antibody conjugate drug. The price structure mainly comes from the investment in drug research and development, the complexity of the production process and the high cost of the antibody conjugation technology itself. Similar ADC drugs are generally in a higher pricing range globally, so the price of somituximab is not abnormal among drugs in the same category. With increasing clinical applications, stable supply chains, and possible policy adjustments, there is still the possibility of price declines in the future.

Overseas, the cost of the European version of the original drug is relatively more indicative. Taking the 100mg/20mL specification as an example, the price of one bottle may be around 38,000 yuan, which may fluctuate due to exchange rates and regional pricing systems. Since the medical systems in Europe mostly adopt unified pricing or government centralized payment mechanisms, their prices are often lower than those in markets with higher self-pay ratios. In the absence of generic drugs in various places, somituximab is still an original product with a relatively fixed price.

Reference materials:https://www.elahere.com/